| Literature DB >> 23851489 |
Georgia Velimezi1, Michalis Liontos, Konstantinos Vougas, Theodoros Roumeliotis, Jirina Bartkova, Maria Sideridou, Ayguel Dereli-Oz, Maciej Kocylowski, Ioannis S Pateras, Kostas Evangelou, Athanassios Kotsinas, Ines Orsolic, Sladana Bursac, Maja Cokaric-Brdovcak, Vassilis Zoumpourlis, Dimitris Kletsas, George Papafotiou, Apostolos Klinakis, Sinisa Volarevic, Wei Gu, Jiri Bartek, Thanos D Halazonetis, Vassilis G Gorgoulis.
Abstract
The DNA damage response (DDR) pathway and ARF function as barriers to cancer development. Although commonly regarded as operating independently of each other, some studies proposed that ARF is positively regulated by the DDR. Contrary to either scenario, we found that in human oncogene-transformed and cancer cells, ATM suppressed ARF protein levels and activity in a transcription-independent manner. Mechanistically, ATM activated protein phosphatase 1, which antagonized Nek2-dependent phosphorylation of nucleophosmin (NPM), thereby liberating ARF from NPM and rendering it susceptible to degradation by the ULF E3-ubiquitin ligase. In human clinical samples, loss of ATM expression correlated with increased ARF levels and in xenograft and tissue culture models, inhibition of ATM stimulated the tumour-suppressive effects of ARF. These results provide insights into the functional interplay between the DDR and ARF anti-cancer barriers, with implications for tumorigenesis and treatment of advanced tumours.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23851489 DOI: 10.1038/ncb2795
Source DB: PubMed Journal: Nat Cell Biol ISSN: 1465-7392 Impact factor: 28.824